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Editorial
Patrick Hunziker
Nanomedicine enabled by computational sciences
Nanomedicine has its roots deeply in experimental 
research: the scanning microscopes have opened the door 
to nano scale analysis, nanomaterials including fuller-
enes, carbon nanotubes, dendrimers, and lipidic and 
polymeric nanomaterials were created as novel construc-
tive building blocks, and the combination of nano-fluid-
ics, single molecule/nanoparticle photonics as analytic 
tools have gone hand in hand to create. Starting in basic, 
experimental science, this very productive and interdisci-
plinary field of nanomedicine (1) has rapidly progressed 
towards preclinical science and clinical application and is 
strongly interacting with related sciences, e.g.,  toxicology, 
stem cell therapies, therapeutic gene therapy, and the 
 clinical sciences.
Nanomedical materials are in most cases supramolec-
ular constructs built up from multiple building blocks that 
belong to different classes, e.g., proteins and synthetic 
polymers, lipids and nucleic acids, metals with a protein 
corona, to mention only a few. These combinations deliver 
an impressive range of innovative functionality and novel 
properties that are appealing for preventive, diagnostic 
and therapeutic application.
While the experimental productivity in the field of 
such new materials is overwhelming, solid and system-
atic understanding of the field is lagging behind. This can 
be explained on one side by the fact that nanomedicine is 
a young scientific field, and on the other side by the chal-
lenge that the large domain of small molecules, combined 
with the large domain of proteins, further combined with 
the large domains of polymers as well as inorganic mate-
rials forms a huge combinatorial universe, representing 
a daunting challenge to a specialist focusing on one spe-
cific method or material, following the evolution of scien-
tific specialization in the last century.
Computational approaches to each individual compo-
nent exist in principle, but are rarely combined:
 – ‘Ab initio’ simulation of small molecules (although 
still challenged by seemingly simple, but as it now 
turns out, challenging problems like the properties 
of water and its interaction with other molecules), 
combined with modeling of polymers (Figure 1);
 – computational proteomics, although still limited in its 
predictive power for key nanomedical questions like 
the structure and interaction of membrane proteins 
with macromolecules and particles;
 – computational approaches to cell biology and systems 
biology, shedding light on the cellular processes that 
can be triggered by cell–nanomaterials interaction
 – computational toxicology, e.g., by prediction of the 
interaction of small molecules with key pathways 
responsible for drug toxicity;
 – computational pharmacokinetic and pharmaco-
dynamic modeling;
 – disease modeling based on individual characteristics, 
a prerequisite for a personalized medicine
 – prognostic modeling for disease outcome and 
individual disease cost-effectiveness;
 – data mining and ‘big data’ approaches to enhance our 
understanding of the large datasets produced daily 
in our labs, clinics, and administration departments, 
which could be of benefit for the medicine of the future.
Publications describing application of such computa-
tional tools to nanomaterials (2), composite analytic 
systems (3) and the interdisciplinary challenges of nano-
medical progress have started to appear, but are still far 
too sparse to render the computational technologies a 
Figure 1 Computational modeling of triblock copolymer composed 
of oxazolines and siloxane. Block copolymers are an important 
building block of complex nanosystems (4).
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factor that significantly accelerates the translation of 
nanoscience towards real-world applications.
Such a field, which might be called “Computational 
Nanomedicine” is therefore almost inexistent at the 
current time, but sorely needed. We therefore challenge 
the computational science community to address this 
gap, to interact with experimental, preclinical and clini-
cal scientists to define needs and to contribute solutions 
that deepen our understanding at the fundamental level, 
that broaden our understanding of our experiments, and 
that help us to predict nanomaterials characteristics and 
nano-bio interaction, up to therapeutic or toxic effects of 
materials and impact on disease course and cost effective-
ness of such approaches.
This journal welcomes submissions that use computa-
tional approaches to advance the field, in the expectation 
that this will accelerate our progress towards a person-
alized, highly effective, innocuous, and cost-effective 
medicine of the future through the application of nano-
medicine (5). 
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